Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370693 · ClinicalTrials.gov registry record · Phase 2
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02370693: Completed Phase 2 study, sponsored by Northwestern University.
NCT02370693 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02370693, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
Primary Outcome
To assess the safety and tolerability of bortezomib with mycophenolate mofetil assessed by the incidence of serious adverse events.
Interventions
- DRUG Placebo
- DRUG Bortezomib
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-01-01 |
| Phase | Phase 2 |
What the finished NCT02370693 record still lists
NCT02370693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02370693 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02370693 about?
NCT02370693 is a clinical study titled "Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis". The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
What is the current status of trial NCT02370693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-03. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT02370693?
The interventions under investigation include: Placebo (DRUG), Bortezomib (DRUG), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT02370693?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02370693's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia